Volume 24 Issue 3-4
Volume 24 Issue 3-4
The Ethics of Assisted Reproductive Technologies
Jun-Jul 2011
The Booming Baby Business
By CRG staff - interview with Debora Spar
The Folly of Geneticizing Criminal Behavior
By Troy Duster
A Synthetic Biology Lab in Berkeley
By Jeremy Gruber, Tina Stevens, Becky McClain
Match, Mate, Trait
By Lisa C. Ikemoto
21st Century Parenting
By Susannah Baruch
Commercial Surrogacy in India
By Vrinda Marwah
IVF and Multiple Embryo Transfers: Everything in Moderation
By CRG staff - interview with Judy Stern
The Fast and the Furious
By Lori Haymon
Abuses of Women’s Human Rights in Third Party Reproduction
By Kathleen Sloan
Finding the Active Voice
By Tina Stevens, Pat Jennings and Diane Beeson
Egg Donation and Eggsploitation
By CRG staff - interview with Jennifer Lahl
Testimonial: Egg Donation Complications
By CRG Staff
Commercial Surrogacy and the Cost of Reproductive “Freedom”
By Marsha Darling
The Southern Baptist Ethics of ARTs
By CRG staff - interview with Barrett Duke
ART’s Minor Issue
By Michele Goodwin
Willful Ignorance
By Abby Lippman
Old Patterns, New Ideas
By Hedva Eyal
Topic update: Congress Raises Ire of Gene Patent Activists
By CRG Staff
Special Topic: Genetic Reductionism
By CRG Staff
Genetics Without Ideology
By Kenneth Weiss
Engineering a Red Herring
By Colin O'Neil
Editor's Note
By Samuel W. Anderson
Search: GeneWatch
The Gene Myths series features incisive, succinct articles by leading scientists disputing the exaggerations and misrepresentations of the power of genes.
View Project
Rapid developments in biotechnology over the last two decades have enabled corporations and scientists to alter nature's handiwork for commercial profit. The patent, a tool originally created to insure that inventors could share in the financial returns and benefits deriving from the use of their nventions, has become the primary mechanism through which the private sector advances its claims to ownership over genes, proteins, and entire organisms.
View Project